Sonja Burgstaller

Grieskirchner Str. 42
Wels, 4600, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study.

A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study.

Journal: Wiener klinische Wochenschrift

Published: December 05, 2019

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.

Journal: Therapeutic advances in medical oncology

Published: July 04, 2019

Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy management.

Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy management.

Journal: Wiener klinische Wochenschrift

Published: December 14, 2018

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.

Journal: British journal of haematology

Published: September 25, 2018

Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia.

Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia.

Journal: Leukemia

Published: September 21, 2018

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.

Journal: Haematologica

Published: September 19, 2018

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.

Journal: Cancer medicine

Published: September 17, 2018

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Journal: Wiener klinische Wochenschrift

Published: May 17, 2018

Austrian recommendations for the management of polycythemia vera.

Austrian recommendations for the management of polycythemia vera.

Journal: Wiener klinische Wochenschrift

Published: March 31, 2018

Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report.

Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report.

Journal: Transplantation proceedings

Published: January 01, 2018

Overexpression of the proneural transcription factor ASCL1 in chronic lymphocytic leukemia with a t(12;14)(q23.2;q32.3).

Overexpression of the proneural transcription factor ASCL1 in chronic lymphocytic leukemia with a t(12;14)(q23.2;q32.3).

Journal: Molecular cytogenetics

Published: December 04, 2017

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

Journal: Leukemia research

Published: October 17, 2017

Showing 1-12 of 44

Last Updated: 09/26/2026